Annual report [Section 13 and 15(d), not S-K Item 405]

Schedule of Deferred Tax Assets and Liabilities (Details)

v3.26.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Income Tax Disclosure [Abstract]    
Net operating loss carry forward – Federal $ 11,507,543 $ 7,566,071
Net operating loss carry forward – State 2,957,337 2,074,542
Stock compensation expense and other 1,322,468 2,794,464
Unrealized gain related to digital asset (75,871)
Purchased in-process R&D 2,394,596 2,477,193
Federal orphan drug credits 1,211,026 1,209,202
Capitalized research and development costs 2,008,637 3,781,193
Total non-current deferred tax assets 21,325,736 19,902,665
Valuation allowance for deferred tax assets (21,325,736) (19,902,665)
Total deferred tax assets
Intangible asset
Total non-current deferred tax liabilities
Total deferred tax asset (liability)